Test Price
2,800 AED✅ Home Collection Available
VEGFA Gene Genetic Test for Microvascular Complications of Type 1 Diabetes
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited next‑generation sequencing with confirmatory Sanger sequencing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection, available daily from 8 AM to 11 PM.
- Post‑Test Support: Telephonic clinical guidance for result interpretation and personalized action planning.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The VEGFA gene genetic test employs clinical‑grade next‑generation sequencing (NGS) to detect pathogenic variants in the VEGFA gene associated with increased risk of microvascular complications in type 1 diabetes—including diabetic retinopathy, nephropathy, and neuropathy. The assay covers the full coding region and flanking intronic boundaries, with all detected variants confirmed by Sanger sequencing to achieve 99.9% analytical sensitivity. This test provides clinically actionable insights to guide personalized surveillance intervals and early intervention strategies.
| Feature | Our Test (DNA Labs UAE) | Closest Alternative |
|---|---|---|
| Precision | 99.9% sensitivity, confirmatory Sanger for all variants | 92‑95% via standard genotyping arrays |
| Method | NGS – full coding region ± flanking introns | Targeted SNP panels only |
| Turnaround | 3–4 weeks from sample receipt | 4–6 weeks, often shipped abroad |
Physician Insight & Safety Protocols
"A positive VEGFA variant does not guarantee development of complications; rather, it signals the need for tighter glycaemic control, regular retinal screening, and monitoring of urinary microalbumin. As a clinical geneticist, I always interpret this test in the context of the patient's HbA1c trajectory, family history, and existing end‑organ damage. Please do not alter your insulin or antihypertensive regimen without discussing the findings with your attending physician."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Medication Advisory
Do Not Discontinue Prescribed Medication
Never stop your insulin, antihypertensives, or other prescribed medications without direct consultation with your doctor. This genetic test is purely predictive and does not replace clinical management decisions.
Safety Exclusion Criteria & Red Flags
- Active acute illness (infection, diabetic ketoacidosis) – reschedule after stabilization.
- Recent blood transfusion (< 3 months) may interfere with cell‑free DNA analysis.
- If you experience sudden vision loss, chest pain, or severe shortness of breath, seek emergency care immediately—this test does not replace acute evaluation.
- This test is not intended for minors without a legally valid consent as per applicable UAE regulations.
Patient FAQ & Clinical Guidance
1. How accurate is the VEGFA gene test for predicting microvascular complications in type 1 diabetes?
This NGS‑based test achieves 99.9% analytical sensitivity for the VEGFA coding region, and every pathogenic variant is confirmed by Sanger sequencing before reporting. This ensures you receive reliable information to guide preventive care with your diabetes management team.
2. What should I do if my result shows a high‑risk VEGFA variant?
A high‑risk variant triggers a personalized action plan. You will receive a telephonic consultation with our clinical geneticist to interpret the variant, and we recommend scheduling advanced eye (retinal photography) and kidney (urinary microalbumin) screening within 30 days. Your diabetes care plan may be adjusted in collaboration with your endocrinologist.
3. Can I take this test if I already have diabetic retinopathy or nephropathy?
Yes, the test can clarify the genetic contribution even after complications have developed. It helps refine prognostic estimates and may influence the frequency of ophthalmic and renal monitoring. Always discuss the results with your specialist to tailor your ongoing care.
UAE Regulatory & Data Privacy Adherence
This test and associated laboratory processes comply with:
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensures confidentiality and security of your genetic information.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governs electronic health data handling.
- Federal Decree‑Law No. 4 of 2016 on Medical Liability – safeguards patient safety and informed consent processes.
All sample processing is performed under ISO 9001:2015 certificate INT/EGQ/2509DA/3139. Results are delivered only to the requesting physician or the patient after identity verification.
Clinical & Logistical Metadata
| Test Name | VEGFA Gene Genetic Test (Microvascular Complications in Type 1 Diabetes) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Whole blood (EDTA tube), extracted DNA, or FTA card spot |
| Methodology Used | Next‑Generation Sequencing (NGS) + Sanger confirmation |
| ICD‑10‑CM Code | E10.40 (Type 1 diabetes with diabetic neuropathy, unspecified) – E10.41, E10.42, E10.43 |
| LOINC Code | 81256-6 (VEGFA gene analysis in blood by NGS) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians